CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 401 enrolled
Drug / intervention
Glycopyrronium /Indacaterol maleatedrug
Likely dose
Glycopyrronium /Indacaterol maleate 50mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02202616
NCT02202616Phase 4Completed
CompareCT.gov

Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)

Novartis Pharmaceuticals·interventional·Posted Jul 29, 2014·Updated Jul 2, 2019

In Brief

A Phase 4 clinical trial evaluating Glycopyrronium /Indacaterol maleate for Chronic Obstructive Pulmonary Disease. Completed, enrolled 401 participants across 1 site.

Detailed Summary

This is a single cohort, prospective post approval study conducted on patients with COPD in Canada. The study will enroll patients that have not responded to their current treatment of tiotropium alone, or who are on the fixed dose combinations fluticasone propionate/salmeterol. Only patients for whom the physician has decided to change treatment due to lack of efficacy will be eligible to be enrolled in the study. Also will evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesCanada
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 29, 2014
Enrollment StartAug 27, 2014
Primary CompletionApr 5, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.9 years ago

Interventions

Glycopyrronium /Indacaterol maleatedrug

Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device